Jennison Associates LLC Decreases Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Jennison Associates LLC lowered its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 28.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 293,588 shares of the company's stock after selling 117,349 shares during the period. Jennison Associates LLC owned approximately 0.59% of Prestige Consumer Healthcare worth $22,926,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. DAVENPORT & Co LLC bought a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $1,212,000. Caprock Group LLC purchased a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $210,000. Pacer Advisors Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 83.0% during the 4th quarter. Pacer Advisors Inc. now owns 3,352 shares of the company's stock valued at $262,000 after buying an additional 1,520 shares during the period. KBC Group NV boosted its stake in shares of Prestige Consumer Healthcare by 28.3% in the 4th quarter. KBC Group NV now owns 2,048 shares of the company's stock worth $160,000 after buying an additional 452 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Prestige Consumer Healthcare by 24.8% in the fourth quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock worth $158,000 after acquiring an additional 435 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on PBH shares. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. Canaccord Genuity Group raised their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Friday, January 24th. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Finally, DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $92.50.

Insider Buying and Selling

In other news, EVP Adel Mekhail sold 9,063 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares of the company's stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded down $0.39 during trading hours on Friday, hitting $86.96. 523,063 shares of the stock traded hands, compared to its average volume of 288,972. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 20.37, a price-to-earnings-growth ratio of 2.43 and a beta of 0.50. Prestige Consumer Healthcare Inc. has a 1 year low of $60.00 and a 1 year high of $88.36. The stock has a 50 day moving average price of $79.23 and a 200 day moving average price of $75.45. The company has a quick ratio of 2.10, a current ratio of 3.68 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.